Quantum BioPharma Ltd. has taken a significant step toward developing a novel treatment for multiple sclerosis by signing an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302.
The company plans to submit the IND to the U.S. Food and Drug Administration in the fourth quarter of 2025, with the goal of initiating a Phase 2 clinical trial. Lucid-21-302, also known as Lucid-MS, represents a potential breakthrough in MS treatment as a patented, non-immunomodulatory neuroprotective therapy.
Preclinical studies have demonstrated the compound's ability to prevent demyelination, a critical mechanism in multiple sclerosis and other neurodegenerative disorders. By targeting myelin degradation, the drug could offer a new approach to managing and potentially halting disease progression.
This development is significant for patients with multiple sclerosis, a chronic neurological condition that currently lacks comprehensive treatment options. If successful, Lucid-21-302 could provide a novel therapeutic strategy that differs from existing immunomodulatory treatments by focusing on neuroprotection.
The advancement of Lucid-MS through the regulatory process represents an important milestone for Quantum BioPharma and potentially offers hope for improved management of multiple sclerosis and related neurodegenerative conditions.
